Introduction
Cryptosporidiosis is a gastrointestinal illness caused by multiple species within the protozoan genus Cryptosporidium, with Cryptosporidium hominis and Cryptosporidium parvum comprising the majority of human disease. Cryptosporidiosis is the second most frequent parasitic gastrointestinal disease worldwide, and a leading cause of morbidity and mortality due to diarrheal illnesses, particularly in immunocompromised hosts and malnourished children who reside in resource-poor countries. Transmission can occur through human-to-human contact, contaminated water sources, or contact with infected animals. Symptoms range from mild and self-limiting to fulminant and chronic, with the host’s degree of immunosuppression being a significant factor in the disease course, particularly in those with deficiencies in T-cell immunity. For patients with persistent disease, nitazoxanide is the only FDA-approved treatment option; however, studies have shown limited efficacy of its use in the most vulnerable populations, including in the immunocompromised and in malnourished children. Given the limited treatment options, preventing disease remains crucial in reducing incidence and prevalence.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Cryptosporidium species are intracellular protozoan parasites belonging to the phylum Apicomplexa, which also includes other human disease-causing protozoans, eg, Toxoplasma, Plasmodium, Babesia, Cyclospora, and Cystoisospora. Currently, at least 44 Cryptosporidium species are known to infect a variety of vertebrates, including mammals, reptiles, birds, and fish.[1] Cryptosporidium hominis and Cryptosporidium parvum are the 2 predominant species causing human disease, accounting for up to 95% of infections. Cryptosporidium hominis infects only humans, whereas Cryptosporidium parvum can infect both animals and humans. Molecular studies have also identified other species as causes of human disease, eg, Cryptosporidium cuniculus, Cryptosporidium meleagridis, Cryptosporidium felis, and Cryptosporidium canis; however, these species are typically found only in the significantly immunosuppressed or malnourished.[2] Transmission of Cryptosporidium occurs by the ingestion of cysts in the environment through the fecal-oral route. This can occur through human-to-human contact, zoonotic exposure, or by consuming contaminated food or water.
Epidemiology
Cryptosporidiosis has a global distribution and is recognized as one of the leading causes of diarrhea across all age groups. Cryptosporidium oocysts are acquired through fecal-oral transmission, most often by ingesting contaminated water or by direct contact with infected persons and animals.[2] Between 2017 and 2022, Cryptosporidium accounted for 74.4% of worldwide waterborne protozoan outbreaks, followed by Giardia at 17.1%. Recreational water and public swimming pools accounted for 92% of water sources, likely because Cryptosporidium is small enough to pass through most standard filters and is chloride-resistant.[3] In terms of foodborne transmission, there have been reports of outbreaks from apple cider, unpasteurized milk, and vegetables.[4][5][6] There are also reports of zoonotic transmission to farmers and veterinary personnel, as cattle, sheep, goats, and pigs can be affected.[7] Person-to-person transmission has been well described in households of infected individuals and in daycare centers, mostly involving Cryptosporidium hominis.[8][9] Sexual transmission has also been described, particularly in men who have sex with men.[10] Infection is generally more common during the warmer months, when recreational water activities are ongoing, and at other times of the year when water runoff from pastures occurs.[11]
Cryptosporidium infections are more prevalent in resource-poor countries. A systematic review and meta-analysis demonstrated a global pooled prevalence of cryptosporidiosis of 7.6%, with an average of 4.3% in developed countries versus 10.4% in developing countries. The highest infection prevalence was observed in Mexico, Bangladesh, and Nigeria at 69.6%, 42.5%, and 34.0%, respectively.[12] The higher prevalence in resource-poor countries is likely secondary to poor hygiene practices, overcrowding, intensive animal farming, open defecation, and a greater number of people living with HIV. Interestingly, outbreaks have occurred less often in resource-poor compared to resource-rich countries, thought to be due to higher immunity from repeated exposure in areas with high endemicity.[13][14] Per the Centers for Disease Control and Prevention summary report, a worldwide estimate of 823,000 cryptosporidiosis cases occurs annually, with 12,609 cases reported in the United States in 2022, of which 45.5% occurred in males and 54.1% in females.[CDC. Cryptosporidiosis NNDSS Summary Report for 2022]
Cryptosporidiosis is known to affect 3 main epidemiological groups: immunocompetent individuals, immunocompromised individuals, and children. For the immunocompromised, people living with HIV have been found to have higher rates of infection, particularly when the CD4+ T cell count is less than 200 cells/µL. In Ghana, a study found a prevalence of 26% in HIV-positive patients with CD4+ T cell count less than 200 cells/µL. Among individuals with CD4+ T cell count less than 50 cells/µL, the prevalence of infection increased to 46%. In patients with CD4+ T cell counts above 200 cells/µL, the prevalence of Cryptosporidium infection was comparable to that of those who were HIV-negative at 6%.[15] The transplant population, including solid organ transplants and bone marrow transplants, has also been found to have higher rates of infection compared to the immunocompetent, with most data coming from kidney transplant recipients.[16] In children, cryptosporidiosis is known to be a major cause of prolonged diarrhea leading to malnutrition, particularly in developing countries. Furthermore, a clear association between income class and age of infection has been noted. In lower- to middle-income classes, children are generally affected by age 2 years. In a prospective case-control study known as the Global Enteric Multicenter Study (GEMS), cryptosporidiosis was found to be the second leading cause of diarrheal illness in children younger than 2 years of age in South Asia and sub-Saharan Africa, with an estimated 7.6 million cases annually and 200,000 deaths attributable to infection.[17] In contrast, children of the higher-income class generally acquire infection at age 5 or older, thought to be due to better hygiene practices that lead to lower rates of fecal-oral transmission in infancy.[13]
Cryptosporidium is also a well-recognized protozoan cause of traveler’s diarrhea, though less common than bacterial pathogens and Giardia. In large surveillance studies of returning travelers, Cryptosporidium accounts for approximately 2% to 11% of protozoal infections, with higher prevalence in those returning from South-Central Asia and sub-Saharan Africa. Children and immunocompromised travelers are at particular risk for more severe or prolonged disease, and over 14% of travelers with cryptosporidiosis may require hospitalization.[18][19]
Pathophysiology
Cryptosporidium is an intracellular yet extracytoplasmic pathogen that completes its entire life cycle within a single host, reproducing both sexually and asexually. The infective stage is known as the oocyst, which is the hardy, spore-form of the parasite found in the environment. Once picked up by a host through fecal-oral transmission, oocysts primarily traverse to the distal small bowel and proximal colon. The oocysts then become activated in the gastrointestinal tract, releasing 4 sporozoites. The sporozoites invade epithelial cells, causing the host membrane to fold over the parasite and form a parasitophorous vacuole. This vacuole allows the parasite to survive and replicate. Although intracellular, the vacuole is located outside the cytoplasm of the cell, which helps it evade host defenses that typically degrade intracytoplasmic vacuoles, such as phagocytosis, antigen-antibody interactions, and protein binding.[20] Inside the vacuole, sporozoites undergo asexual reproduction to become trophozoites, which then produce merozoites.
Merozoites invade new cells, continue asexual reproduction, or begin sexual reproduction, leading to sporulation and the formation of new oocysts. Some oocysts become thin-walled and continue the autoinfectious cycle, while others become thick-walled and are excreted back into the environment through feces.[2] The thick-walled oocysts are particularly resilient to multiple environmental stressors, allowing them to survive up to 6 to 8 months outside a host, especially in aquatic environments. They can also survive in temperatures ranging from -20 to 60 °C, with a study showing oocysts remained infectious after 24 weeks of storage at 0 to 20 °C.[21] Studies have demonstrated that oocysts become inactivated at -20 °C or lower after 1 week and can also be killed by microwave heating and pasteurization.[22] Oocysts are also known to be chlorine-resistant, and their small size can evade many filtration systems not designed to capture organisms 1 µm or smaller, thereby facilitating Cryptosporidium outbreaks in public swimming pools and recreational waters.[23]
Histopathology
Cryptosporidium is found on the brush border of intestinal epithelial cells. Oocysts appear basophilic on hematoxylin and eosin stain and are acid-fast positive with Ziehl–Neelsen and Kinyoun stain. They are smaller (4-6 µm), which helps differentiate them from other acid-fast-positive intracellular protozoa, including Cyclospora (8-10 µm) and Cystoisospora (25-30 µm). The location of the parasitophorous vacuole also helps differentiate between the protozoa: Cryptosporidium is extracytoplasmic, found on the surface of the enterocyte, whereas Cyclospora is intracytoplasmic. Infected intestinal epithelium undergoes rapid turnover, causing dysplasia. Crypt hyperplasia and villous atrophy also occur, leading to the disruption of intestinal architecture. This loss of barrier integrity contributes to a decrease in intestinal absorptive function and an increase in membrane permeability.[24]
Toxicokinetics
Studies in seronegative, healthy volunteers inoculated with varying doses of Cryptosporidium oocysts have shown that as few as 10 to 100 oocysts can cause infection. The median time to disease onset after inoculation is about 7 days, with a range of 2 to 28 days. Infected hosts have been observed to excrete anywhere from 10,000 to 1 billion oocysts, with oocyst shedding typically lasting 7 to 30 days. Higher inoculum doses showed no statistically significant differences in shedding duration, illness duration, or disease severity. This suggests it is not necessarily the amount of organisms that leads to virulence, but rather that host factors and strain differences may play a pivotal role.[25][26] For example, in contrast to seronegative volunteers, seropositive volunteers required an inoculum more than 20-fold higher and showed less oocyst shedding, suggesting that host response can reduce the number of oocysts produced in those who have been previously infected.[27]
History and Physical
Cryptosporidiosis has a wide clinical spectrum ranging from asymptomatic shedding of oocysts to severe, cholera-like diarrheal illness. In symptomatic individuals, clinical symptoms vary with epidemiological factors and the host's immune status. In immunocompetent individuals in high-income countries, symptoms are generally mild, presenting as nonbloody diarrhea. Diarrhea can be associated with other typical coexisting symptoms of gastroenteritis, including vomiting, dehydration, fatigue, abdominal cramping, low-grade fevers, and anorexia.[28]
In the HIV population, the clinical spectrum can also vary from being asymptomatic and self-limiting to severe and persistent. Individuals with HIV who have CD4+ T cell counts less than 50 cells/µL are at increased risk for extraintestinal manifestations of Cryptosporidium, specifically within the pancreatic and biliary systems, including acalculous cholecystitis, sclerosing cholangitis, and pancreatitis.[29] Cryptosporidium also is known to infect transplant patients, with main symptoms being diarrhea, abdominal pain, weight loss, and vomiting. Extraintestinal infections within the biliary system in kidney transplant patients have also been reported.[16] Children who are affected also tend to have watery diarrhea, vomiting, dehydration, and may develop signs of malnutrition.
Evaluation
Cryptosporidium infections can be diagnosed through microscopy, immunoassay, and molecular testing. Standard stool microscopy methods can easily miss oocysts due to their small size; however, specialized techniques improve detection, including modified acid-fast staining and immunofluorescence. Cryptosporidium oocysts are smaller (4-6 µm), which helps differentiate them from other acid-fast-positive intracellular protozoa, including Cyclospora (8-10 µm) and Cystoisospora (25-30 µm). Oocysts stain bright pink or red on a blue-green background with modified acid-fast staining. Studies have shown sensitivities ranging from 37% to 79.1% with the Ziehl-Neelsen stain and from 66.7% to 91.6% with Kinyoun's stain. Immunofluorescence microscopy highlights oocysts in bright green on a black background and is known to be more sensitive than acid-fast staining, making it the gold standard for microscopy testing.
Immunoassays, eg, direct fluorescent antibody and enzyme-linked immunosorbent assay, are also used, with specificity ranging from 91% to 100%. However, the sensitivities of commercially available immunoassays have been found to vary widely, ranging from 47% to 100%. As a result, molecular methods have been increasingly utilized for their high sensitivity and specificity. Several multiplex polymerase chain reaction (PCR) kits are available in the United States that include Cryptosporidium testing, such as Luminex xTAG gastrointestinal pathogen panel, BioFire FilmArray, and BD Max parasitic panel. These panels are noted to have a sensitivity of 95% to 100% and a specificity of 99.6% to 100%.[30][31]
Oocyst shedding in the stool can be intermittent rather than continuous; therefore, organisms can be missed on a single test.[32] If suspicion of cryptosporidiosis remains high despite a negative initial test, sending up to 3 separate stool samples over a few days is reasonable to increase the chances of detecting actively shedding oocysts. Ultrasound (US), CT, and ERCP/MRCP are the primary imaging modalities for evaluating hepatobiliary and pancreatic cryptosporidiosis, with ultrasound being the best initial diagnostic test when biliary disease is suspected. The most common findings include biliary duct dilatation, wall thickening, and features of sclerosing cholangitis. The radiologic findings are nonspecific and may resemble those seen in cytomegalovirus infection and microsporidiosis.[33]
Treatment / Management
The mainstay treatment for cryptosporidiosis is supportive therapy with fluid and electrolyte replacement. Nutritional status should be monitored closely and supplemented as needed, particularly in children and patients who are malnourished at baseline. Antimotility agents, eg, loperamide, can be used in mild to moderate disease, although their efficacy in severe disease is limited. People living with HIV who are not on HIV treatment should have highly active antiretroviral therapy initiated as soon as possible, given the importance of the cellular immune system to control the infection, which is fundamental to symptom improvement and parasite clearance in this population.[34][CDC. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2023]
To date, no antiparasitic drug has demonstrated reliable cure rates, especially in the immunocompromised host. Nitazoxanide is the only FDA-approved medication for the treatment of cryptosporidiosis. Studies have shown improvements in symptoms and clearance of parasitemia in immunocompetent individuals treated with nitazoxanide. Yet these results are not consistently observed in immunocompromised hosts or malnourished children, underscoring the importance of an intact immune system in clearing infection. Duration of use is not well-defined. Those who are immunocompetent have shown improvement within 3 to 5 days, while the immunocompromised generally require treatment for at least 2 weeks, sometimes months, depending on symptom improvement.
The current recommendations for nitazoxanide in moderate-to-severe or persistent disease (greater than 2 weeks) are 3 days in immunocompetent patients and 14 days in immunocompromised patients. Paromomycin is a non-FDA-approved alternative medication to consider if nitazoxanide is not available. Although studies have demonstrated increased parasite clearance with paromomycin, there is significant variation in clinical response, and it has been shown to be inferior to nitazoxanide. Few studies have used azithromycin and rifaximin in the HIV population and immunocompromised children with favorable clinical results. This has led to the use of combination therapy with azithromycin or rifaximin plus nitazoxanide or paromomycin in diseases that are refractory to monotherapy, or don´t have access to those drugs. Other medications, eg, clarithromycin, spiramycin, and clofazimine, have not demonstrated clinical benefit in patients with cryptosporidiosis.[35][36]
As in HIV infected patients, where restoring immunity is critical with ARV drugs, in solid-organ transplant patients, reduction of immunosuppression is considered a cornerstone of management because cellular immune recovery is critical for parasite clearance, and persistent immunosuppression is associated with prolonged or relapsing infection and worse outcomes. The evidence base for this approach is primarily case series and expert consensus, as controlled trials are lacking. However, strategies with some positive results have been reported in the medical literature, eg, tapering or discontinuing mycophenolate mofetil, reducing calcineurin inhibitors (especially tacrolimus), or switching from tacrolimus to cyclosporine.[37][38]
Differential Diagnosis
The differential diagnosis of diarrheal illness caused by cryptosporidiosis includes infectious and noninfectious etiologies, including:
- Bacterial
- Campylobacter spp
- Clostridium difficile
- Escherichia coli
- Salmonella spp
- Shigella spp
- Vibrio spp, including cholerae and noncholerae species
- Yersinia enterocolitica
- Viral
- Adenovirus
- Astrovirus
- Cytomegalovirus (including biliopancreatic symptoms)
- Norovirus
- Rotavirus
- Sapovirus
- Protozoan
- Cyclospora cayetanensis
- Cystoisospora belli
- Entamoeba histolytica
- Enterocytozoon bieneusi
- Giardia lamblia
- Noninfectious
- Tumors (Colorectal cancer, carcinoid)
- Celiac disease
- Inflammatory bowel disease
- Irritable bowel syndrome
- Small intestinal bacterial overgrowth
Prognosis
In the immunocompetent, gastrointestinal symptoms of Cryptosporidium infection are usually self-limiting after 1 to 2 weeks, with a median duration of 7 days. Studies have reported that up to one-third to one-half of cases with initial symptom resolution recur, defined as the return of diarrhea after at least 2 days of normal stools.[39] Immunosuppressed individuals are more likely to have a chronic course, sometimes with diarrhea lasting longer than 6 weeks. The degree of immunosuppression plays a large role in prognosis. For instance, in the HIV population, both the severity and chronicity of disease seem to correlate with CD4 count, highlighting the importance of T-cell immunity.
In those with CD4+ T cell counts greater than 150 cells/µL, disease is often mild and self-limiting, similar to that in the immunocompetent population. In contrast, HIV-positive individuals with a CD4+ T cell count less than 100 cells/µL may develop more of a chronic illness with frequent bulky stools, weight loss, and malabsorption. A minority will develop fulminant disease, defined as greater than 21 stools per day, particularly those with a CD4+ T cell count less than 50 cells/µL.[28] Initiation of highly active antiretroviral therapy in the HIV patient infected with Cryptosporidium has often been shown to provide resolution of disease once their CD4+ T cell count reconstitutes.[40] Severely immunosuppressed patients who go on to develop biliary involvement tend to have higher mortality with shortened survival times.[41]
Complications
Prospective cohort studies that follow patients for up to 10 years after Cryptosporidium infection have demonstrated long-term sequelae in both adults and children. In adults, those with a history of cryptosporidiosis were 3 times more likely to report consistent abdominal symptoms and 2 times more likely to report consistent joint pain. New onset of irritable bowel syndrome, inflammatory bowel disease, and lactose intolerance were also reported at higher rates.[42] Other nonintestinal sequelae commonly seen include eye pain, intermittent headaches, dizziness, and fatigue.[43] In contrast, patients who acquired infection in childhood were less likely to report ongoing abdominal pain or joint pain.
The main complication of childhood infection is malnutrition. Studies have shown that even in subclinical or asymptomatic infection, cryptosporidiosis in children has been associated with growth stunting, wasting, and becoming underweight.[44][45] The severity of malnutrition has been linked with infection at age 2 years or younger and living in resource-poor countries. A few reasons have been speculated for why malnutrition is more severe in children who reside in resource-poor countries, including exposures to higher inoculum infections, a tendency for multiple exposures, and children being more malnourished at baseline.[46] In kidney transplants, severe cases of diarrheal illness have led to elevated tacrolimus levels and graft failure.[16]
Deterrence and Patient Education
Cryptosporidiosis is a gastrointestinal illness caused by the parasite Cryptosporidium, characterized by the following:
- Infection occurs through ingestion of contaminated food and water, or by coming into contact with sick people (including with sexual contact), or animals.
- Typical symptoms of cryptosporidiosis are diarrhea, abdominal pain, nausea, and low-grade fevers.
- Cryptosporidiosis is usually a self-limiting illness that does not require treatment.
- Symptoms usually last 2 to 10 days.
- Patients should talk to their healthcare practitioner if symptoms are severe, their immune system is suppressed, or if illness lasts longer than 2 weeks.
The following education and preventive measures should be discussed with patients, in particular with immunosuppressed patients, people in contact with patients with cryptosporidiosis, and travelers to high-prevalence areas:
- Preferably, hands should be washed with soap and water for at least 20 seconds.
- Avoid hand sanitizers, as alcohol does not kill Cryptosporidium.
- Keep surfaces clean by using hydrogen peroxide-based disinfectants.
- Avoid chlorine-based disinfectants, like bleach, as they do not kill Cryptosporidium.
- Avoid drinking or accidentally swallowing water from swimming pools, lakes, or ponds.
- Do not use untreated or unfiltered well water for drinking, showering, cooking, or brushing teeth.
- Avoid drinking tap water when traveling to highly endemic areas; drink bottled water instead.
- Avoid contact with animals that are sick with diarrheal illness.
- Wash all fruits and vegetables with safe water.
- Avoid ingesting unpasteurized products (eg, milk, cider, and cheese).
- Patients with diarrhea should avoid swimming during the illness and for at least 2 weeks after diarrhea has resolved.
- Patients with diarrhea should avoid sexual activity during that time and for at least 2 weeks after diarrhea has resolved.
For hospitalized patients with cryptosporidiosis, standard precautions are recommended for all, with contact precautions added for diapered or incontinent patients for the duration of illness or to control institutional outbreaks, according to CDC guidelines. The CDC's 2007 Guideline for Isolation Precautions specifies that for Cryptosporidium species, standard precautions should be used, with contact precautions implemented for diapered or incontinent persons for the duration of illness or to control institutional outbreaks.[47] Contact precautions include the use of gloves and gowns, the use of dedicated patient care equipment when possible, and enhanced environmental cleaning.[48]
Clinicians should practice hand hygiene before and after each patient contact using soap and water. When possible, single-patient rooms are preferred for patients requiring contact precautions. Some experts recommend that severely immunocompromised patients (especially those with HIV and CD4 counts <100 cells/mm³) should not share a room with a patient with cryptosporidiosis due to the potential for fomite transmission.[NIH Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV][NIH Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. 2026] During outbreaks, single-patient rooms with private bathrooms are particularly important for patients with poor hygiene or fecal incontinence.[1] The most effective disinfectants include hydrogen peroxide, steam sterilization, and UV-C light. In the United States, cryptosporidiosis is a nationally notifiable disease.[CDC. Notifiable Disease. 2024][CDC Cryptosporidiosis NNDSS Summary Report for 2022]
Pearls and Other Issues
Given the lack of effective treatment options, prevention remains key to help reduce the spread of Cryptosporidium. Standard precautions should be practiced, including washing with soap and water. Alcohol-based regimens should be avoided as they are not effective against oocysts. Most chlorine-based disinfectants, eg, bleach, should also be avoided due to their ineffectiveness. Chlorine dioxide, hydrogen peroxide, and ammonia are chemical compounds that are effective at killing oocysts. Heating processes, eg, pasteurization, boiling water, and microwaving, reach temperatures above 60 °C, which desiccate oocysts, rendering them nonviable.[23] With water sources, filtration, particularly systems that filter organisms less than 1 µm, remains the mainstay of prevention, given resistance to chlorination. Those with diarrheal illness should avoid swimming in recreational water for at least 2 weeks after the illness subsides to prevent contamination. People with exposure to farm animals should avoid contact with animals with diarrheal illness. Those who practice anogenital intercourse should use safe practices with condoms, practice good hygiene to avoid fecal-oral transmission, and avoid sexual activity when diarrheal illness is present. People traveling to high-endemic places should avoid drinking tap water, particularly those who are immunosuppressed. To date, no controlled studies or retrospective reviews have recommended or demonstrated the efficacy of chemoprophylaxis with nitazoxanide or other antimicrobial medications.
Although the connection between cryptosporidiosis and cellular immunity has been established, the role of humoral immunity is less understood. Some studies report an association between Cryptosporidium infection and primary humoral deficiencies, eg, common variable immunodeficiency, IgA deficiency, and hypogammaglobulinemia; however, it remains unclear whether these underlying immune defects increase susceptibility or affect disease severity.[49] Other studies have shown that after initial infection with Cryptosporidium, elevated Cryptosporidium-specific IgG and IgA are associated with lower rates of disease recurrence, suggesting the importance of humoral immunity, at least in reinfection.[50] This has led to research in potential vaccination development.
However, vaccine development has faced many challenges, including identifying an appropriate target antigen from the parasite's vast genetic repertoire.[51] Ongoing genetic studies are being conducted to uncover the roles of these genes and to determine whether any can serve as therapeutic targets for vaccines and medications.[52] Another area where data are lacking is the potential association between the gut microbiota and its influence on the natural course of Cryptosporidium infection, including susceptibility, severity, and chronicity of disease.[53] Finally, further research is needed to elucidate effective monotherapy or combination therapy in the treatment of cryptosporidiosis, particularly in the immunocompromised host and malnourished children who are the most susceptible to severe and chronic disease.
Enhancing Healthcare Team Outcomes
Cryptosporidiosis is a globally significant protozoal gastrointestinal infection caused primarily by Cryptosporidium hominis and Cryptosporidium parvum, transmitted via the fecal–oral route through contaminated water, food, or zoonotic exposure. The organism invades intestinal epithelial cells and resides in a parasitophorous vacuole, enabling immune evasion and autoinfection. Clinical manifestations range from mild, self-limited diarrhea in immunocompetent individuals to severe, chronic, or extraintestinal disease in immunocompromised patients, particularly those with impaired T-cell immunity. Diagnosis requires a high index of suspicion and the use of sensitive modalities, such as immunofluorescence or molecular assays, due to intermittent oocyst shedding. Management is primarily supportive with fluid and electrolyte replacement, while nitazoxanide remains the only approved therapy, with limited efficacy in high-risk populations. Immune restoration is critical for disease resolution.
Interprofessional collaboration is essential for optimizing outcomes, reducing complications, and preventing transmission. Physicians and advanced practitioners lead diagnostic evaluation and management decisions, while emergency clinicians triage disease severity and determine the need for hospitalization. Nurses deliver frontline supportive care, monitor for clinical deterioration, and reinforce patient education. Pharmacists ensure appropriate medication use and evaluate therapeutic options in refractory cases, and nutritionists address malnutrition to support recovery. Infectious disease specialists guide complex management, particularly in immunocompromised patients. Public health professionals coordinate outbreak response and prevention strategies. Effective communication and shared decision-making across the care team promote timely interventions, adherence to evidence-based care, and improved patient safety and quality of care outcomes.
References
Ryan UM, Feng Y, Fayer R, Xiao L. Taxonomy and molecular epidemiology of Cryptosporidium and Giardia - a 50 year perspective (1971-2021). International journal for parasitology. 2021 Dec:51(13-14):1099-1119. doi: 10.1016/j.ijpara.2021.08.007. Epub 2021 Oct 26 [PubMed PMID: 34715087]
Level 3 (low-level) evidenceZhang Y, Jiang P, Yin J, Zhu G. Pathogenicity and virulence of Cryptosporidium. Virulence. 2025 Dec:16(1):2597642. doi: 10.1080/21505594.2025.2597642. Epub 2025 Dec 4 [PubMed PMID: 41319271]
Bourli P, Eslahi AV, Tzoraki O, Karanis P. Waterborne transmission of protozoan parasites: a review of worldwide outbreaks - an update 2017-2022. Journal of water and health. 2023 Oct:21(10):1421-1447. doi: 10.2166/wh.2023.094. Epub [PubMed PMID: 37902200]
Blackburn BG, Mazurek JM, Hlavsa M, Park J, Tillapaw M, Parrish M, Salehi E, Franks W, Koch E, Smith F, Xiao L, Arrowood M, Hill V, da Silva A, Johnston S, Jones JL. Cryptosporidiosis associated with ozonated apple cider. Emerging infectious diseases. 2006 Apr:12(4):684-6 [PubMed PMID: 16704822]
Ali M, Ji Y, Xu C, Hina Q, Javed U, Li K. Food and Waterborne Cryptosporidiosis from a One Health Perspective: A Comprehensive Review. Animals : an open access journal from MDPI. 2024 Nov 14:14(22):. doi: 10.3390/ani14223287. Epub 2024 Nov 14 [PubMed PMID: 39595339]
Level 3 (low-level) evidenceNasser AM. Transmission of Cryptosporidium by Fresh Vegetables. Journal of food protection. 2022 Dec 1:85(12):1737-1744. doi: 10.4315/JFP-22-152. Epub [PubMed PMID: 36048914]
Galuppi R, Piva S, Castagnetti C, Sarli G, Iacono E, Fioravanti ML, Caffara M. Cryptosporidium parvum: From foal to veterinary students. Veterinary parasitology. 2016 Mar 30:219():53-6. doi: 10.1016/j.vetpar.2016.02.001. Epub 2016 Feb 3 [PubMed PMID: 26921039]
McKerr C, Chalmers RM, Elwin K, Ayres H, Vivancos R, O'Brien SJ, Christley RM. Cross-sectional household transmission study of Cryptosporidium shows that C. hominis infections are a key risk factor for spread. BMC infectious diseases. 2022 Feb 2:22(1):114. doi: 10.1186/s12879-022-07086-y. Epub 2022 Feb 2 [PubMed PMID: 35105330]
Level 2 (mid-level) evidenceKorpe P, Ni Z, Kabir M, Alam M, Ferdous T, Ara R, Munday RM, Haque R, Duggal P. Prospective Cohort Study of Cryptosporidium Infection and Shedding in Infants and Their Households. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 Jun 16:76(12):2178-2186. doi: 10.1093/cid/ciad059. Epub [PubMed PMID: 36750491]
To B, Chai N, Fitzpatrick C, Richardson D. Factors associated with Cryptosporidium in men who have sex with men: A systematic review. International journal of STD & AIDS. 2024 Aug:35(9):668-674. doi: 10.1177/09564624241249203. Epub 2024 Apr 26 [PubMed PMID: 38671340]
Level 1 (high-level) evidenceRamirez NE, Wang P, Lejeune J, Shipitalo MJ, Ward LA, Sreevatsan S, Dick WA. Effect of tillage and rainfall on transport of manure-applied Cryptosporidium parvum oocysts through soil. Journal of environmental quality. 2009 Nov-Dec:38(6):2394-401. doi: 10.2134/jeq2008.0432. Epub 2009 Oct 29 [PubMed PMID: 19875795]
Level 2 (mid-level) evidenceDong S, Yang Y, Wang Y, Yang D, Yang Y, Shi Y, Li C, Li L, Chen Y, Jiang Q, Zhou Y. Prevalence of Cryptosporidium Infection in the Global Population: A Systematic Review and Meta-analysis. Acta parasitologica. 2020 Dec:65(4):882-889. doi: 10.2478/s11686-020-00230-1. Epub 2020 Jun 8 [PubMed PMID: 32514837]
Level 1 (high-level) evidenceYang X, Guo Y, Xiao L, Feng Y. Molecular Epidemiology of Human Cryptosporidiosis in Low- and Middle-Income Countries. Clinical microbiology reviews. 2021 Mar 17:34(2):. doi: 10.1128/CMR.00087-19. Epub 2021 Feb 24 [PubMed PMID: 33627442]
Bouzid M, Kintz E, Hunter PR. Risk factors for Cryptosporidium infection in low and middle income countries: A systematic review and meta-analysis. PLoS neglected tropical diseases. 2018 Jun:12(6):e0006553. doi: 10.1371/journal.pntd.0006553. Epub 2018 Jun 7 [PubMed PMID: 29879110]
Level 1 (high-level) evidenceSarfo FS, Frickmann H, Dompreh A, Osei Asibey S, Boateng R, Weinreich F, Osei Kuffour E, Norman BR, Di Cristanziano V, Feldt T, Eberhardt KA. High Clinical Burden of Cryptosporidium spp. in Adult Patients with Acquired Immunodeficiency in Ghana. Microorganisms. 2024 Oct 26:12(11):. doi: 10.3390/microorganisms12112151. Epub 2024 Oct 26 [PubMed PMID: 39597540]
Kosik-Bogacka D, Łanocha-Arendarczyk N, Korzeniewski K, Mularczyk M, Kabat-Koperska J, Ziętek P, Marchelek-Myśliwiec M. Cryptosporidium spp. Infection in Adult Kidney Transplant Patients: A Systematic Review and Meta-Analysis. Journal of clinical medicine. 2024 Oct 25:13(21):. doi: 10.3390/jcm13216395. Epub 2024 Oct 25 [PubMed PMID: 39518534]
Level 1 (high-level) evidenceKotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acácio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet (London, England). 2013 Jul 20:382(9888):209-22. doi: 10.1016/S0140-6736(13)60844-2. Epub 2013 May 14 [PubMed PMID: 23680352]
Level 2 (mid-level) evidenceWeitzel T, Wichmann O, Mühlberger N, Reuter B, Hoof HD, Jelinek T. Epidemiological and clinical features of travel-associated cryptosporidiosis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2006 Sep:12(9):921-4 [PubMed PMID: 16882300]
Level 2 (mid-level) evidenceWeitzel T, Brown A, Libman M, Perret C, Huits R, Chen L, Leung DT, Leder K, Connor BA, Menéndez MD, Asgeirsson H, Schwartz E, Salvador F, Malvy D, Saio M, Norman FF, Amatya B, Duvignaud A, Vaughan S, Glynn M, GeoSentinel Network, Angelo KM. Intestinal protozoa in returning travellers: a GeoSentinel analysis from 2007 to 2019. Journal of travel medicine. 2024 Jun 3:31(4):. doi: 10.1093/jtm/taae010. Epub [PubMed PMID: 38245913]
Abdallah D, Viscogliosi E, Certad G. Cryptosporidium-host interactions: What's new? Current research in parasitology & vector-borne diseases. 2025:8():100285. doi: 10.1016/j.crpvbd.2025.100285. Epub 2025 Jun 19 [PubMed PMID: 40689036]
Fayer R, Trout JM, Jenkins MC. Infectivity of Cryptosporidium parvum oocysts stored in water at environmental temperatures. The Journal of parasitology. 1998 Dec:84(6):1165-9 [PubMed PMID: 9920307]
Peng X, Murphy T, Holden NM. Evaluation of the effect of temperature on the die-off rate for Cryptosporidium parvum oocysts in water, soils, and feces. Applied and environmental microbiology. 2008 Dec:74(23):7101-7. doi: 10.1128/AEM.01442-08. Epub 2008 Oct 10 [PubMed PMID: 18849452]
Helmy YA, Hafez HM. Cryptosporidiosis: From Prevention to Treatment, a Narrative Review. Microorganisms. 2022 Dec 13:10(12):. doi: 10.3390/microorganisms10122456. Epub 2022 Dec 13 [PubMed PMID: 36557709]
Level 3 (low-level) evidenceWallbank BA, Pardy RD, Brodsky IE, Hunter CA, Striepen B. Cryptosporidium impacts epithelial turnover and is resistant to induced death of the host cell. mBio. 2024 Aug 14:15(8):e0172024. doi: 10.1128/mbio.01720-24. Epub 2024 Jul 12 [PubMed PMID: 38995074]
Chappell CL, Okhuysen PC, Sterling CR, DuPont HL. Cryptosporidium parvum: intensity of infection and oocyst excretion patterns in healthy volunteers. The Journal of infectious diseases. 1996 Jan:173(1):232-6 [PubMed PMID: 8537664]
Chappell CL, Okhuysen PC, Langer-Curry R, Widmer G, Akiyoshi DE, Tanriverdi S, Tzipori S. Cryptosporidium hominis: experimental challenge of healthy adults. The American journal of tropical medicine and hygiene. 2006 Nov:75(5):851-7 [PubMed PMID: 17123976]
Chappell CL, Okhuysen PC, Sterling CR, Wang C, Jakubowski W, Dupont HL. Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G. The American journal of tropical medicine and hygiene. 1999 Jan:60(1):157-64 [PubMed PMID: 9988341]
Balendran T, Iddawela D, Lenadora S. Cryptosporidiosis in a Zoonotic Gastrointestinal Disorder Perspective: Present Status, Risk Factors, Pathophysiology, and Treatment, Particularly in Immunocompromised Patients. Journal of tropical medicine. 2024:2024():6439375. doi: 10.1155/2024/6439375. Epub 2024 Nov 5 [PubMed PMID: 39534184]
Level 3 (low-level) evidenceNaseer M, Dailey FE, Juboori AA, Samiullah S, Tahan V. Epidemiology, determinants, and management of AIDS cholangiopathy: A review. World journal of gastroenterology. 2018 Feb 21:24(7):767-774. doi: 10.3748/wjg.v24.i7.767. Epub [PubMed PMID: 29467548]
O'Leary JK, Sleator RD, Lucey B. Cryptosporidium spp. diagnosis and research in the 21(st) century. Food and waterborne parasitology. 2021 Sep:24():e00131. doi: 10.1016/j.fawpar.2021.e00131. Epub 2021 Aug 20 [PubMed PMID: 34471706]
Luka G, Samiei E, Tasnim N, Dalili A, Najjaran H, Hoorfar M. Comprehensive review of conventional and state-of-the-art detection methods of Cryptosporidium. Journal of hazardous materials. 2022 Jan 5:421():126714. doi: 10.1016/j.jhazmat.2021.126714. Epub 2021 Jul 21 [PubMed PMID: 34325293]
Johansen ØH, Abdissa A, Bjørang O, Zangenberg M, Sharew B, Alemu Y, Moyo S, Mekonnen Z, Langeland N, Robertson LJ, Hanevik K. Oocyst Shedding Dynamics in Children with Cryptosporidiosis: a Prospective Clinical Case Series in Ethiopia. Microbiology spectrum. 2022 Aug 31:10(4):e0274121. doi: 10.1128/spectrum.02741-21. Epub 2022 Jun 14 [PubMed PMID: 35699433]
Level 2 (mid-level) evidenceChen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. The New England journal of medicine. 2002 May 30:346(22):1723-31 [PubMed PMID: 12037153]
Maggi P, Larocca AM, Quarto M, Serio G, Brandonisio O, Angarano G, Pastore G. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2000 Mar:19(3):213-7 [PubMed PMID: 10795595]
Diptyanusa A, Sari IP. Treatment of human intestinal cryptosporidiosis: A review of published clinical trials. International journal for parasitology. Drugs and drug resistance. 2021 Dec:17():128-138. doi: 10.1016/j.ijpddr.2021.09.001. Epub 2021 Sep 21 [PubMed PMID: 34562754]
Lu Y, Zhang X, Guan Z, Ji R, Peng F, Zhao C, Gao W, Gao F. Molecular pathogenesis of Cryptosporidium and advancements in therapeutic interventions. Parasite (Paris, France). 2025:32():7. doi: 10.1051/parasite/2025001. Epub 2025 Feb 4 [PubMed PMID: 39902829]
Bhadauria D, Goel A, Kaul A, Sharma RK, Gupta A, Ruhela V, Gupta A, Vardhan H, Prasad N. Cryptosporidium infection after renal transplantation in an endemic area. Transplant infectious disease : an official journal of the Transplantation Society. 2015 Feb:17(1):48-55. doi: 10.1111/tid.12336. Epub 2015 Jan 12 [PubMed PMID: 25620388]
Roberts MB, Fishman JA. Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Oct 5:73(7):e1302-e1317. doi: 10.1093/cid/ciaa1189. Epub [PubMed PMID: 32803228]
Adler S, Widerström M, Lindh J, Lilja M. Symptoms and risk factors of Cryptosporidium hominis infection in children: data from a large waterborne outbreak in Sweden. Parasitology research. 2017 Oct:116(10):2613-2618. doi: 10.1007/s00436-017-5558-z. Epub 2017 Aug 4 [PubMed PMID: 28776228]
Zardi EM, Picardi A, Afeltra A. Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy. 2005 Jul:51(4):193-6 [PubMed PMID: 16006765]
Hashmey R, Smith NH, Cron S, Graviss EA, Chappell CL, White AC Jr. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine. 1997 Mar:76(2):118-39 [PubMed PMID: 9100739]
Level 3 (low-level) evidenceBoks M, Lilja M, Widerström M, Karling P, Lindam A, Sjöström M. Persisting symptoms after Cryptosporidium hominis outbreak: a 10-year follow-up from Östersund, Sweden. Parasitology research. 2023 Jul:122(7):1631-1639. doi: 10.1007/s00436-023-07866-8. Epub 2023 May 18 [PubMed PMID: 37199767]
Hunter PR, Hughes S, Woodhouse S, Raj N, Syed Q, Chalmers RM, Verlander NQ, Goodacre J. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004 Aug 15:39(4):504-10 [PubMed PMID: 15356813]
Khan MA, Haque MA, Tariqujjaman M, Faruque A, Ahmed T, Mahfuz M. Impact of asymptomatic Cryptosporidium infection on nutritional status in children under two: a multi-country cohort study. BMC nutrition. 2025 Oct 21:11(1):190. doi: 10.1186/s40795-025-01183-2. Epub 2025 Oct 21 [PubMed PMID: 41121211]
Khalil IA, Troeger C, Rao PC, Blacker BF, Brown A, Brewer TG, Colombara DV, De Hostos EL, Engmann C, Guerrant RL, Haque R, Houpt ER, Kang G, Korpe PS, Kotloff KL, Lima AAM, Petri WA Jr, Platts-Mills JA, Shoultz DA, Forouzanfar MH, Hay SI, Reiner RC Jr, Mokdad AH. Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study. The Lancet. Global health. 2018 Jul:6(7):e758-e768. doi: 10.1016/S2214-109X(18)30283-3. Epub [PubMed PMID: 29903377]
Boks M, Lilja M, Lindam A, Widerström M, Persson A, Karling P, Sjöström M. Long-term symptoms in children after a Cryptosporidium hominis outbreak in Sweden: a 10-year follow-up. Parasitology research. 2025 Jan 25:124(1):13. doi: 10.1007/s00436-025-08455-7. Epub 2025 Jan 25 [PubMed PMID: 39862254]
Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. American journal of infection control. 2007 Dec:35(10 Suppl 2):S65-164 [PubMed PMID: 18068815]
Level 1 (high-level) evidenceShane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, Langley JM, Wanke C, Warren CA, Cheng AC, Cantey J, Pickering LK. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Nov 29:65(12):e45-e80. doi: 10.1093/cid/cix669. Epub [PubMed PMID: 29053792]
Level 1 (high-level) evidenceCohn IS, Henrickson SE, Striepen B, Hunter CA. Immunity to Cryptosporidium: Lessons from Acquired and Primary Immunodeficiencies. Journal of immunology (Baltimore, Md. : 1950). 2022 Dec 15:209(12):2261-2268. doi: 10.4049/jimmunol.2200512. Epub [PubMed PMID: 36469846]
Kabir M, Alam M, Nayak U, Arju T, Hossain B, Tarannum R, Khatun A, White JA, Ma JZ, Haque R, Petri WA Jr, Gilchrist CA. Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition. PLoS pathogens. 2021 Jun:17(6):e1009445. doi: 10.1371/journal.ppat.1009445. Epub 2021 Jun 28 [PubMed PMID: 34181697]
Merolle M, Striepen B, Hunter CA. Parasite and host immune factors that impact the development of a mucosal vaccine for Cryptosporidium. Mucosal immunology. 2025 Aug:18(4):782-792. doi: 10.1016/j.mucimm.2025.05.002. Epub 2025 May 14 [PubMed PMID: 40379259]
Shaw S, Cohn IS, Baptista RP, Xia G, Melillo B, Agyabeng-Dadzie F, Kissinger JC, Striepen B. Genetic crosses within and between species of Cryptosporidium. Proceedings of the National Academy of Sciences of the United States of America. 2024 Jan 2:121(1):e2313210120. doi: 10.1073/pnas.2313210120. Epub 2023 Dec 26 [PubMed PMID: 38147547]
Rahman SU, Mi R, Zhou S, Gong H, Ullah M, Huang Y, Han X, Chen Z. Advances in therapeutic and vaccine targets for Cryptosporidium: Challenges and possible mitigation strategies. Acta tropica. 2022 Feb:226():106273. doi: 10.1016/j.actatropica.2021.106273. Epub 2021 Dec 11 [PubMed PMID: 34906550]
Level 3 (low-level) evidence